Table 5. Perioperative treatments.
| Perioperative treatment | KGCA (2018) | JGCA (2018) | CSCO (2021) | NCCN (2021) | ESMO (2016) | |
|---|---|---|---|---|---|---|
| Neoadjuvant chemotherapy | ||||||
| Recommendation | Inconclusive | Weakly recommended | Grade I | Category 1 | Grade A | |
| (Extensive LN metastases) | (cT3-4aN+M0) | (cT2 or higher, any N) | (cT2 or higher, any N) | |||
| Regimen | ECF, FP, FLOT | Not mentioned | SOX | FLOT, Fluoropyrimidine + oxaliplatin | FLOT | |
| Neoadjuvant chemoradiotherapy | ||||||
| Recommendation | Inconclusive | Not mentioned | Grade I | Category 2B | Not mentioned | |
| (Gastric cancer invading the EGJ: cT3-4aN+M0) | ||||||
| Adjuvant chemotherapy | ||||||
| Recommendation | Strong for | Recommended | Grade I | Category 1 | Grade A | |
| (Stage II or III) | (Stage II or III) | (Stage II or III) | (Primary D2 LND) | (Primary surgery with ≥Stage IB) | ||
| Regimen | S-1, XELOX | S-1, XELOX, S-1 + docetaxel (Stage III) | S-1, XELOX (Stage II) | XELOX, 5-FU + oxaliplatin | S-1, XELOX | |
| XELOX, SOX (Stage III) | ||||||
| Adjuvant chemoradiotherapy | ||||||
| Recommendation | Weak for | Not mentioned | Grade I | Category 2A | Grade B | |
| (<D2 LND and/or R1 resection) | (<D2 LND and/or R1 or R2 resection) | |||||
This table only includes the CSCO “Grade I recommendations,” NCCN “Preferred Regimens.”
KGCA = Korean Gastric Cancer Association; JGCA = Japanese Gastric Cancer Association; CSCO = Chinese Society of Clinical Oncology; NCCN = National Comprehensive Cancer Network; ESMO = European Society for Medical Oncology; ECF = epirubicin, cisplatin, and fluorouracil; FP = fluorouracil and cisplatin; FLOT = fluorouracil, leucovorin, oxaliplatin, and docetaxel; SOX = S-1 and oxaliplatin; DOS = docetaxel, oxaliplatin, and S-1; EGJ = esophagogastric junction; XELOX = capecitabine and oxaliplatin; 5-FU, 5-fluorouracil; LND = lymph node dissection.